$AMBS News - Amarantus to Present at Two Upcoming Investor Conferences

SAN FRANCISCO and GENEVA, - (http://www.financialnewsmedia.com News Alert) - Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it will be presenting at two upcoming investor conferences.



Event: 2015 Marcum Microcap Conference

Date: Thursday, May 28, 2015

Time: 2:30 p.m. EDT / 11:30 a.m. PDT

Location: Grand Hyatt, New York, NY



Event: LD Micro Invitational

Date: Tuesday, June 2, 2015

Time: 1:30 p.m. EDT / 10:30 a.m. PDT

Location: Luxe Sunset Boulevard, Los Angeles, CA

A webcast of the LD Micro presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.



About Amarantus BioScience Holdings, Inc.



Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS\' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson\'s disease levodopa-induced dyskinesia, adult ADHD and Alzheimer\'s aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS\' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer\'s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson\'s disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF\'s discovery.